CTNM
Income statement / Annual
Last year (2024), Contineum Therapeutics, Inc. Class A Common Stock's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Contineum Therapeutics, Inc. Class A Common Stock's net income was -$42.26 M.
See Contineum Therapeutics, Inc. Class A Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$50.00 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$329,000.00
|
$0.00
|
| Gross Profit |
$0.00
|
$50.00 M
|
-$329,000.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
| Research and Development Expenses |
$38.42 M
|
$27.60 M
|
$16.89 M
|
$22.36 M
|
| General & Administrative Expenses |
$12.47 M
|
$6.32 M
|
$5.83 M
|
$6.29 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$329,000.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.47 M
|
$6.32 M
|
$5.50 M
|
$6.29 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$92,000.00
|
-$91,000.00
|
| Operating Expenses |
$50.89 M
|
$33.92 M
|
$22.39 M
|
$28.65 M
|
| Cost And Expenses |
$0.00
|
$33.92 M
|
$22.72 M
|
$28.65 M
|
| Interest Income |
$8.91 M
|
$4.61 M
|
$761,000.00
|
$77,000.00
|
| Interest Expense |
$0.00
|
$208,000.00
|
$388,000.00
|
$332,000.00
|
| Depreciation & Amortization |
$0.00
|
$195,000.00
|
$329,000.00
|
$325,000.00
|
| EBITDA |
-$50.89 M |
$23.57 M |
-$23.54 M |
-$28.34 M |
| EBITDA Ratio |
0
|
0.47
|
0
|
0
|
| Operating Income Ratio |
0
|
0.32
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.64 M
|
$7.09 M
|
-$1.53 M
|
-$354,000.00
|
| Income Before Tax |
-$42.26 M
|
$23.17 M
|
-$24.25 M
|
-$29.00 M
|
| Income Before Tax Ratio |
0
|
0.46
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$450,000.00
|
$0.00
|
$241,000.00
|
| Net Income |
-$42.26 M
|
$22.72 M
|
-$24.25 M
|
-$29.00 M
|
| Net Income Ratio |
0
|
0.45
|
0
|
0
|
| EPS |
-2.18 |
1.36 |
-0.97 |
-1.74 |
| EPS Diluted |
-2.18 |
1.28 |
-0.97 |
-1.63 |
| Weighted Average Shares Out |
$19.35 M
|
$16.67 M
|
$25.13 M
|
$16.67 M
|
| Weighted Average Shares Out Diluted |
$19.35 M
|
$17.76 M
|
$25.13 M
|
$17.76 M
|
| Link |
|
|
|
|
